Conference Call and Live Audio Webcast Scheduled for Today at 4:30 pm ET
JACKSONVILLE, Fla., May 31, 2017 /PRNewswire/ --
Recent Corporate and Clinical Developments:
• Appointed Dr. Richard Kenney as Head of Clinical Development
• Continued advancing multiple Phase 2 clinical studies of lead vaccine candidate
• TPIV 200 in ovarian and triple-negative breast cancers
• Progressed preclinical development of proprietary PolyStart™ vaccine expression technology
Anticipated 2017 Milestones:
• 2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
• 3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
• 3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
• 3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
• 4Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
• Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer
TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
To read full press release, please click here.
JACKSONVILLE, Fla., May 31, 2017 /PRNewswire/ --
Recent Corporate and Clinical Developments:
• Appointed Dr. Richard Kenney as Head of Clinical Development
• Continued advancing multiple Phase 2 clinical studies of lead vaccine candidate
• TPIV 200 in ovarian and triple-negative breast cancers
• Progressed preclinical development of proprietary PolyStart™ vaccine expression technology
Anticipated 2017 Milestones:
• 2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
• 3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
• 3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
• 3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
• 4Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
• Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer
TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
To read full press release, please click here.
